Enforcement Watch

Marketplace: about 315,000 enrollments (760,000+ people) confirmed unauthorized and cancelled August 31; about $2.2 billion in advance premium tax credits to be returned (CMS estimate)

September 22, 2026

Analysis: CMS Cancelled 315,000 Marketplace Enrollments Covering More Than 760,000 People. What Exactly Was Found?

Interim final rule: moratorium on new 2027 agent and broker registrations without a 2026 agreement, to February 1, 2027

September 22, 2026

Analysis: CMS Cancelled 315,000 Marketplace Enrollments Covering More Than 760,000 People. What Exactly Was Found?

SB 329: investigations of licensed alcohol and drug treatment facilities

September 27, 2026

California 2026 Final Legislative Ledger

SB 991: categories of citations for residential care facilities for the elderly

September 30, 2026

California 2026 Final Legislative Ledger

SB 849: reinstatement of a physician's certificate surrendered after sexual misconduct

September 27, 2026

Medical Board of California page

Intraosseous needle sets recalled after reports the stylet can lock during insertion

BD letter July 30, 2026 · FDA early alert August 4, 2026

United States — FDA, Center for Devices and Radiological Health. Five BD powered-driver intraosseous needle kits (15Ga, 15–55mm) were manufactured with out-of-tolerance dimensions, which can allow the obturator to rotate and lock into the needle hub during insertion. FDA reports that as of July 22 BD had reported 45 serious injuries and four deaths associated with the issue. Affected lots were distributed between September 30, 2024 and June 12, 2026; the powered driver is not affected.

ExposureThe failure occurs at insertion, in the settings where intraosseous access is used at all — out-of-hospital cardiac arrest and severe trauma. Affected stock is to be destroyed rather than returned, which makes this an inventory task with a clinical deadline.

For physiciansA needle already placed and functioning needs no further step, and one already used and removed needs no follow-up. FDA states expressly that an unsuccessful intraosseous attempt does not exhaust vascular access: further peripheral attempts or central access remain available on clinical judgement and local protocol.

What it does not establishAn early alert is FDA notifying the public of a potentially high-risk issue while it is still reviewing information. A Class I designation for this 2026 event is not posted in FDA’s device-recall database at the date of reading and is not asserted here; the separately classified 2022 BD intraosseous recall is a different event. The injury and death counts are reports made to FDA, not adjudicated causation.

Primary source: FDA — early alert · BD recall announcement, 31 July 2026 · affected lot list

FDA discussion paper on regulating generative-AI medical devices

Issued August 18, 2026 · feedback closed October 19, 2026 · docket FDA-2026-N-7874

United States — FDA, Center for Devices and Radiological Health, Digital Health Center of Excellence. A two-axis risk-assessment framework, a premarket approach built on competency assessment (non-clinical benchmarking followed by clinical confirmation), risk-proportionate postmarket monitoring options, and considerations for foundation models and agentic systems. Each section asks questions rather than setting expectations.

ExposureIf the competency model is carried forward, the evidence a vendor must hold before a generative tool reaches a clinic changes shape — and so does what an institution can be expected to have checked before deploying one.

For physiciansThe comment window is the only stage at which a clinician’s account of how these tools actually behave in practice enters the record. It closed 19 October 2026.

What it does not establishNot a rule, not draft guidance, not final guidance. FDA states it is not proposing or implementing policy and is not communicating regulatory expectations, and the paper does not address whether the approaches discussed fall within existing legal authority. No duty arises from this record.

Primary source: FDA — discussion paper and request for feedback · news release, 18 August 2026 · docket FDA-2026-N-7874

CY 2027 Medicare Physician Fee Schedule proposed rule

Published July 16, 2026 · comments closed September 14, 2026

United States — CMS. CMS-1848-P, 91 FR 43842. Placed on public display July 14, 2026, published July 16, 2026; comment period closed at close of business September 14, 2026. Finalized policies would generally take effect January 1, 2027. No obligation arises from this record until a final rule issues.

Update, 5 November 2026. The final rule has issued: CMS placed CMS-1848-F on public display on November 4, 2026; Federal Register publication is set for November 9, 2026, and its policies generally take effect January 1, 2027. Final conversion factors: $32.95 for qualifying APM participants and $32.63 for everyone else (proposed: $33.17 and $32.84). The record above is kept as the record of the proposal.

ExposureA split conversion factor converts alternative-payment participation from a strategic preference into a financial fork. An efficiency adjustment applied to work RVUs redistributes income across specialties without any change in what the physician does.

For physiciansThe comment window is the only period in which a physician's objection can change the rule. It closed 14 September 2026; from then on the argument moves to litigation, where the standard of review is far less favourable.

Primary source: CMS — CMS-1848-P regulation notice · CMS — CY 2027 PFS fact sheet · CMS — CMS-1848-F regulation notice · CMS — CY 2027 PFS final rule fact sheet

Related analysis: Telehealth Payment After Temporary Flexibilities · Value-Based Payment and the Risk of Undertreatment · Quality Measures and Gaming · Productivity Targets and Independence

Interoperability Standards and Prior Authorization for Drugs (CMS-0062-P)

Published April 14, 2026 · comment period closed June 15, 2026 · final rule pending

United States — CMS / HHS. Would extend the electronic prior-authorization framework built by CMS-0057-F to drugs under both the medical and pharmacy benefit, require impacted payers to report API endpoints and usage metrics, and adopt certain HL7 FHIR standards under HIPAA Administrative Simplification. Most proposed provisions carry an October 1, 2027 compliance date. Proposed only; the October 2027 dates are not current duties.

Primary source: CMS — CMS-0062-P proposed rule

CMS proposes to replace the 6 percent provider-tax threshold with state-specific ceilings

CMS-2452-P, 91 FR (2026-14897) — Medicaid Program; Amending the Indirect Hold Harmless Threshold of Health Care-Related Taxes; released 21 July 2026, published 23 July 2026

July 23, 2026 · verified August 17, 2026

What happenedThe rule would implement section 71115 of Public Law 119-21 by replacing the long-standing 6 percent indirect hold-harmless threshold with thresholds based on taxes enacted and imposed as of 4 July 2025, effective 1 October 2026, with a phase-down for most permissible classes in Medicaid expansion states from 1 October 2027. It would also add services of health insurers as a new permissible class and create new reporting requirements. Comments are due 21 September 2026. The CMS Office of the Actuary estimates the rule would reduce federal expenditures by $246 billion over ten years.

What it changes for physiciansThis is a financing rule with clinical consequences: provider taxes fund a large share of the non-federal Medicaid share, and a state that loses that revenue adjusts provider rates, eligibility processing, or managed-care capitation — not its statutory obligations. For a physician seeing Medi-Cal patients, the exposure is rate and access pressure two budget cycles out, not a compliance duty.

What it does not doProposed. The 1 October 2026 statutory date belongs to section 71115, not to this rule; nothing in the proposal binds a state or a provider until a final rule issues.

Primary source: Federal Register — CMS-2452-P (23 July 2026) · CMS — CMS-2452-P fact sheet

Related analysis: medicaid financing mechanics provider taxes and state directed payments · public participation in regulation · beyond the u s model comparative governance of medicaid financing mechanics provider taxes and state directed payments

Ways and Means advances the Medicare Advantage prior-authorization bill to the full House

H.R. 3514, Improving Seniors' Timely Access to Care Act; full-committee markup, 15 July 2026

July 15, 2026 · verified August 16, 2026

What happenedThe committee marked up a health package including H.R. 3514 and reported it out; the bill advances to the full House. As introduced, it would require an electronic prior-authorization programme and enrollee-protection standards for plan years beginning on or after 1 January 2028, with transparency requirements from 1 January 2027.

What it changes for physiciansThis is the legislative track running alongside the CMS interoperability rules. If it passes in this form, the API duties CMS built by rule acquire a statutory floor and a real-time-decision definition that a rule alone can revise.

What it does not doA reported bill is not law. Nothing in it binds any plan today, and committee approval does not schedule a floor vote.

Primary source: House Ways and Means — full-committee markup notice, 15 July 2026 · Congress.gov — H.R. 3514 (119th Congress)

Related analysis: electronic pa and cms interoperability rules · investigating pa delays · fhir apis and coverage decisions

DMHC fines Blue Shield of California $300,000 over denied newborn-care payments

DMHC enforcement action announced 23 June 2026; Knox-Keene Health Care Service Plan Act

June 23, 2026 · verified August 17, 2026

What happenedThe Department announced a $300,000 administrative penalty against Blue Shield of California for denying payments for newborn care.

What it changes for physiciansNewborn care is the recurring pattern in this line of enforcement: the infant is a new enrollee whose eligibility posts after the encounter, so the claim is denied on enrollment grounds for care the plan must cover. A denial in that shape is a plan-side defect worth escalating rather than writing off.

What it does not doAn administrative penalty against a plan is not a finding about any physician or any individual claim, and it does not itself reopen denied claims.

Primary source: DMHC — press releases index · DMHC — Enforcement Actions Database

Related analysis: grievances exhaustion and clinical complaints · investigating pa delays

2026 National Health Care Fraud Takedown: 455 defendants charged

DOJ 2026 National Health Care Fraud Takedown, announced 23 June 2026

June 23, 2026 · verified August 16, 2026

What happenedDOJ announced charges against 455 defendants, including 90 doctors and other licensed medical professionals, in schemes involving over $6.5 billion in alleged false claims. Cases were brought in 56 federal districts across 45 states and territories, with all 50 state Medicaid Fraud Control Units participating, and over $182 million in assets seized. Alongside the charges, CMS suspended 1,079 providers and revoked billing privileges for 1,403.

What it changes for physiciansThe administrative half is the part physicians underestimate. A payment suspension or revocation lands before any adjudication and does not wait for a plea, a verdict, or a licensing decision — which is why the CMS numbers, not the defendant count, are the operational risk.

What it does not doEvery charge is an allegation. No finding of guilt exists until conviction or plea, and dispositions will be added to this record as they issue rather than replacing it.

Primary source: Justice Department — takedown announcement, 23 June 2026 · HHS-OIG — 2026 National Health Care Fraud Takedown case index

Related analysis: the false claims act in healthcare · interpreting enforcement statistics · complaint is not finding

OIG finds post-acute prior-authorization denial rates far above the all-services rate

OEI-09-24-00331 (skilled nursing facilities) and OEI-09-24-00330 (long-term care hospitals and inpatient rehabilitation facilities), completed 8 June 2026, posted 11 June 2026

June 11, 2026 · verified August 16, 2026

What happenedReviewing June 2024 data from the 19 largest Medicare Advantage organizations, OIG found 12 percent of SNF admission requests denied, with plan-level rates from 0.4 to 23 percent; 18 percent of SNF denials were appealed, and 95 percent of appealed denials were overturned in the enrollee's favour. Denial rates reached 65 percent for long-term care hospital requests and 54 percent for inpatient rehabilitation, with the three largest organizations among the highest.

What it changes for physiciansA 95 percent overturn rate is an argument about initial determinations, not about appeals working. For the discharging physician it means a denial of post-acute placement is worth appealing on the clinical record you already have, and that the delay itself — days in an acute bed — is the harm to document.

What it does not doAn audit finding is not an enforcement action and establishes no violation by any named plan. OIG's data cannot separate denials that should never have issued from approvals granted on later documentation.

Primary source: HHS-OIG — MAOs overturned nearly all appealed SNF prior-authorization denials (OEI-09-24-00331) · HHS-OIG — work-plan record for the post-acute prior-authorization reviews

Related analysis: investigating pa delays · peer to peer review · medicare advantage risk coding integrity · grievances exhaustion and clinical complaints

OHCA proposes the regulations that implement AB 1415's notice regime

Proposed revisions to the material change transaction and cost-and-market-impact-review regulations (Cal. Code Regs., tit. 22, div. 7, ch. 11.5), text dated May 2026, implementing AB 1415 (Ch. 641, Stats. 2025)

May 15, 2026 · verified August 17, 2026

What happenedOHCA published proposed regulatory text for informal comment and accepted comments until 11 June 2026. The text extends the notice framework to noticing entities — private equity groups, hedge funds, newly created entities and certain management services organizations — and carries the 90-day advance filing requirement across to them. Until regulations are enacted, OHCA's own FAQ states that noticing entities must at a minimum provide written notice under Health and Safety Code section 127507(c)(2)(A).

What it changes for physiciansThis answers the question the statute left open on 1 January: an MSO transaction closing now is already inside the notice duty, and the interim standard is written notice rather than the full filing package. Waiting for final regulations is not a compliance position.

What it does not doProposed and, on the record read, not adopted. The definitions and ownership thresholds in the draft may change before adoption, and no compliance date attaches to the draft itself.

Primary source: HCAI — Laws & Regulations (OHCA rulemaking to implement AB 1415; comments to 11 June 2026) · HCAI — proposed CMIR regulation text for informal comment, May 2026 · HCAI — AB 1415 frequently asked questions

Related analysis: hospital consolidation and antitrust enforcement · private equity and the practice · certificate of need laws

MHRA publishes the draft Medical Devices (Amendment) Regulations 2026 for Great Britain

Draft Medical Devices (Amendment) Regulations 2026, notified on the World Trade Organisation portal 8 May 2026; stakeholder impact survey closed 19 June 2026

May 8, 2026 · verified August 17, 2026

What happenedThe draft statutory instrument sets new pre-market requirements for medical devices and in vitro diagnostics entering the Great Britain market, replacing requirements carried over from the retained EU directives. MHRA invited comment from WTO members and, separately, from industry, approved bodies, healthcare providers and patients through a survey that closed at 23:59 on 19 June 2026.

What it changes for physiciansFor a clinician the consequence is downstream and practical: an instrument that changes classification and conformity assessment changes which devices and diagnostic software reach a British clinic, and on what evidence. Healthcare providers were named as consultees, which means the clinical view of a device's real-world performance was solicited at the drafting stage rather than after adoption.

What it does not doA draft statutory instrument. It creates no duty, and adoption requires Parliament; the timetable reported for adoption and entry into force is not part of the notified draft and is not verified here.

Primary source: GOV.UK — MHRA invites views on proposed changes to medical device regulation

Related analysis: global ai standards · how the fda reviews ai enabled devices · pre market vs post market surveillance

Uniform procedural requirements imposed on notified bodies under MDR and IVDR

Commission Implementing Regulation (EU) 2026/977 — uniform requirements for conformity assessment and notified bodies (MDR/IVDR, Annex VII), adopted May 2026

May 2026 · verified August 17, 2026

What happenedThe Implementing Regulation sets standardised procedural requirements for the conformity assessment activities of notified bodies under the Medical Devices Regulation and the In Vitro Diagnostic Regulation. It sits alongside, and is separate from, the Commission's targeted simplification proposal for MDR and IVDR published on 16 December 2025 (COM(2025) 1023 final), which remains in the ordinary legislative procedure before the Parliament and Council.

What it changes for physiciansCertification delay is the mechanism by which European device rules reach a clinic: a diagnostic or software device that cannot get through a notified body does not arrive. Standardising quotation, timeline and audit practice is aimed at that bottleneck, and it is in force now, unlike the larger revision.

What it does not doAn implementing regulation binds notified bodies, not clinicians, and it does not change the substantive safety and performance requirements of MDR or IVDR. The December 2025 simplification proposal is a proposal only; nothing in it applies. The exact adoption date within May 2026 is not verified here.

Primary source: European Commission — medical devices, new regulations (lists Implementing Regulation (EU) 2026/977 and the 16 December 2025 proposal) · European Commission — COM(2025) 1023 final (proposal text)

Related analysis: global ai standards · pre market vs post market surveillance · regulatory framework across the ai lifecycle

Health Canada publishes pre-market guidance for machine-learning-enabled medical devices

Health Canada, Pre-market guidance for machine learning-enabled medical devices (Class II–IV), April 2026

April 2026 · verified August 17, 2026

What happenedThe guidance sets Health Canada's expectations for machine-learning-enabled devices: the medical purpose must be stated for any Class II, III or IV device; predetermined change control plans provide a route to pre-authorise planned model changes that address a known risk; and manufacturers are expected to apply SGBA Plus, collecting and analysing disaggregated data on sub-populations across training, test and clinical data. Health Canada adopts the IMDRF terms and definitions for these devices.

What it changes for physiciansThe disaggregated-data expectation is the part a physician can use. A device authorised in Canada should be able to say how it performed in the populations a clinic actually serves, and the guidance makes that a documented submission element rather than a courtesy.

What it does not doGuidance states current thinking and is not binding law; it imposes no new statutory obligation and may be revised. Dated April 2026 on the departmental page; the exact publication day is not verified here.

Primary source: Health Canada — Pre-market guidance for machine learning-enabled medical devices · Health Canada — guidance document (PDF)

Related analysis: continuous learning algorithms · regulatory framework across the ai lifecycle · global ai standards

TGA guidance: AI is regulated by intended purpose, including generative clinical decision support

TGA guidance, Artificial intelligence (AI) and medical device software regulation, updated February 2026

February 2026 · verified August 17, 2026

What happenedThe guidance states that regulation is triggered by the manufacturer's intended purpose rather than by the presence of AI, and it names clinical decision support tools that use generative AI to give diagnostic or treatment recommendations as regulated devices. Devices must be included in the Australian Register of Therapeutic Goods unless excluded or exempt, and synthetic data will generally not substitute for clinical data in meeting clinical evidence requirements.

What it changes for physiciansIntended purpose is the operative concept, so a tool marketed as an assistant is regulated on what it is for, not what it is called. Where a practice deploys a generative tool for a purpose outside its registered intended purpose, the guidance's own remedy is to cease supply or revise the purpose and re-submit — which makes off-label deployment the deploying organisation's exposure.

What it does not doGuidance interprets the Therapeutic Goods Act framework; it is not itself legislation. The exact date of the February 2026 update, and the listing of software as a medical device among the TGA's stated compliance priorities for 2026–2027, are not verified here.

Primary source: TGA — Artificial intelligence (AI) and medical device software regulation · TGA — overview of software and artificial intelligence

Related analysis: ai assisted diagnosis and physician responsibility · generative ai in medical documentation · global ai standards

DMHC fines Health Net plans $1.3 million for mishandling provider payment disputes

DMHC enforcement action announced 4 February 2026; Knox-Keene Act provider dispute resolution requirements

February 4, 2026 · verified August 17, 2026

What happenedThe Department announced penalties totalling $1.3 million against Health Net plans for mishandling provider payment disputes.

What it changes for physiciansProvider dispute resolution has acknowledgment and resolution deadlines, and a plan's pattern of missing them is itself the violation — separate from whether any individual claim was payable. A practice that documents dispute dates is documenting the element the Department enforces on.

What it does not doA penalty against a plan resolves no individual dispute and makes no finding about any provider's billing. The per-plan allocation of the total was not read at source.

Primary source: DMHC — press releases index · DMHC — Enforcement Actions Database

Related analysis: grievances exhaustion and clinical complaints · peer to peer review

Consolidated Appropriations Act, 2026 extends Medicare telehealth flexibilities through 2027

H.R. 7148, Consolidated Appropriations Act, 2026 (119th Cong.), signed 3 February 2026

February 3, 2026 · verified August 16, 2026

What happenedThe Act funds federal departments for the remainder of FY2026 and extends expiring programmes and authorities, including the Medicare telehealth flexibilities that had lapsed days earlier. The extension runs through 31 December 2027 and was applied retroactively across the gap.

What it changes for physiciansGeographic and originating-site relief, the expanded practitioner list, audio-only coverage and the deferral of the in-person requirement for tele-behavioural care all continue — but on a date certain, not permanently. Any 2028 schedule built on them is built on an authority that expires first.

What it does not doAn appropriations extension is not permanence. The same provisions have now lapsed and been restored twice in four months.

Primary source: Congress.gov — H.R. 7148, Consolidated Appropriations Act, 2026 · GovInfo — enrolled text of H.R. 7148

Related analysis: telehealth payment after temporary flexibilities

Medicare telehealth flexibilities lapse for three days

Expiry of the extension enacted by the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (H.R. 5371), signed 12 November 2025, which carried the flexibilities to 30 January 2026; gap closed retroactively by H.R. 7148

January 31, 2026 · verified August 17, 2026

What happenedThe extension in force through 30 January 2026 expired, and the flexibilities lapsed until the 3 February 2026 Act restored them retroactively.

What it changes for physiciansClaims for services furnished in the gap were payable in the end, but only after the fact. The operational lesson is the one practices keep re-learning: hold rather than cancel, because a retroactive fix cannot recreate a cancelled appointment.

What it does not doRecorded as historical: accurate as of its date, superseded in effect by the 3 February statute. The record states the lapse and its dates, not a pinpoint section designation within H.R. 5371.

Primary source: Congress.gov — H.R. 5371 (119th Congress), signed 12 November 2025 · Congress.gov — H.R. 7148, Consolidated Appropriations Act, 2026

Related analysis: telehealth payment after temporary flexibilities

DMHC fines Anthem Blue Cross $15 million over member-complaint failures

DMHC enforcement action announced 30 January 2026; Knox-Keene Act grievance and complaint requirements

January 30, 2026 · verified August 17, 2026

What happenedThe Department announced a $15 million penalty against Anthem Blue Cross for what it described as longstanding and widespread failures in handling member complaints.

What it changes for physiciansIt is the largest California plan penalty of the year to date and it is about grievance handling, not medical necessity. Where a patient's grievance goes unanswered, the physician's clinical record is often the only contemporaneous account of the request — which is what makes the chart the evidence in a complaint case.

What it does not doAn administrative penalty is not a judicial finding and does not establish that any particular enrollee's care was wrongly denied.

Primary source: DMHC — press releases index · DMHC — Enforcement Actions Database

Related analysis: grievances exhaustion and clinical complaints · complaint is not finding

Telemedicine prescribing of controlled substances continues through 2026, on a temporary rule

Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, 90 FR (2025-24123), published 31 December 2025; effective 1 January 2026 through 31 December 2026

January 1, 2026 · verified August 17, 2026

What happenedDEA, jointly with HHS, extended the pandemic-era telemedicine prescribing flexibilities for a fourth time. A DEA-registered practitioner may prescribe a Schedule II–V controlled substance following a telemedicine encounter without a prior in-person evaluation, provided the conditions in the temporary rule are met. HHS announced the extension on 2 January 2026 and stated that it buys time to finalise the proposed Special Registration for Telemedicine.

What it changes for physiciansThe date is the whole point: this authority ends on 31 December 2026, and it is the fourth time it has been extended by temporary rule rather than replaced by a permanent framework. A practice that treats tele-prescribing of controlled substances as settled policy is scheduling into an authority with a fixed expiry and no successor in force.

What it does not doA temporary rule. It changes nothing about the requirement that prescriptions issue for a legitimate medical purpose by a licensed practitioner in compliance with federal and state law, and it does not create the special registration that would replace it.

Primary source: Federal Register — Fourth Temporary Extension (31 December 2025) · HHS — announcement of the extension, 2 January 2026

Related analysis: telehealth payment after temporary flexibilities · opioid prescribing and regulatory scrutiny

CY 2026 Physician Fee Schedule takes effect with two conversion factors

CY 2026 Medicare Physician Fee Schedule final rule, 90 FR (2025-19787), effective 1 January 2026

January 1, 2026 · verified August 16, 2026

What happenedFor the first time Medicare pays under two conversion factors: $33.5675 for qualifying participants in advanced alternative payment models and $33.4009 for everyone else. The rule also applied an efficiency adjustment of −2.5 percent to the work RVUs of non-time-based services and made virtual direct supervision permanent.

What it changes for physiciansA headline increase and a code-level cut arrive together, so the net effect depends entirely on a practice's mix: procedural, non-time-based work absorbs the efficiency adjustment while time-based codes do not. The APM differential also converts model participation from a bonus question into a rate question.

What it does not doIn force. The 2.5 percent statutory increase inside the conversion factors is a one-year addition, not a new baseline.

Primary source: Federal Register — CY 2026 Physician Fee Schedule final rule · CMS — Physician Fee Schedule

Related analysis: value based payment and the risk of undertreatment · productivity targets and independence · quality measures and gaming